C-Path and CDISC announce therapeutic area user guide for Duchenne Muscular Dystrophy

Critical Path Institute (C-Path) and The Clinical Data Interchange Standards Consortium (CDISC) announce the open availability of a Duchenne Muscular Dystrophy Therapeutic Area User Guide ( TAUG-DMD v1.0), which describes the most common clinical concepts relevant to Duchenne studies using the CDISC standard format. This format allows datasets from different sources to be compared or combined for data collection, sharing, and analyses.

Version 1.0 of TAUG-DMD focuses on representing data using the CDISC Study Data Tabulation Model (SDTM). Types of data covered include genetic information and imaging data, as well as results from a variety of disease measures including cardiac, musculoskeletal, and pulmonary function assessments. Data standards are also being developed for a variety of functional tests.

"We are delighted to partner with C-Path's Duchenne Regulatory Science Consortium [D-RSC] to create a standard for Duchenne muscular dystrophy that will facilitate improved data collection, sharing, and analysis, giving patients the hope that new treatments may be discovered," said David R. Bobbitt, MSc, MBA, President and CEO, CDISC.

The US Food and Drug Administration (FDA) Binding Guidance requires that sponsors submit data in FDA-supported CDISC formats listed in the FDA Data Standards Catalog. CDISC standards have been adopted and used in more than 90 countries, and are required by regulatory authorities in the US and Japan. To date, Therapeutic Area Standards have been developed for more than 30 different disease areas. Use of these standards from the start of clinical research programs has proven capable of saving both time and resources. Researchers in Duchenne are encouraged to implement these standards into their processes.

"I avidly follow DMD drugs in the pipeline that are soon to be evaluated by the FDA," said Christopher (Buddy) Cassidy, patient representative for the D-RSC. "I am very enthusiastic about the role the CDISC data standard for Duchenne will play in the near future with particular regard to FDA approval. A standardized method for will in turn make it easier for clinicians, researchers, drug development companies, and the FDA to share and compare data. Only through the constant exchange of like sets of data can we truly evaluate the effectiveness of new DMD treatments." He added, "As a patient with Duchenne, I consider myself fortunate being born into the time I was. I get to witness the beginning of a promising age of genetic medicine and revolutionary new treatment."

"We are excited to publish the new Duchenne Therapeutic Area User Guide," said Jane Larkindale, DPhil, Executive Director of the D-RSC. "We hope the research community rapidly adopts the standard in new studies, which will allow future data to be compared, contrasted, and combined in a methodical manner, and lead to a more rapid and comprehensive understanding of disease progression and drug effects."

TAUG-DMD v1.0 was developed under the Coalition for Accelerating Standards and Therapies (CFAST), with clinical advice and input from D-RSC members. CFAST, a joint initiative of CDISC and C-Path, was formed to accelerate clinical research and medical product development by creating and maintaining data standards, tools, and methods for conducting research in therapeutic areas important to public health, with invaluable support and advice from such organizations as the National Cancer Institute, Innovative Medicines Initiative, TransCelerate, and regulatory agencies including FDA, Japan's Pharmaceutical and Medical Devices Agency, and the European Medicines Agency.

Duchenne is a rare, fatal, genetic neuromuscular disorder that is diagnosed in childhood and primarily affects boys. It causes progressive loss of muscle, resulting in loss of the ability to walk, loss of upper body strength, progressive breathing issues, cardiomyopathy, and premature death. Although there are medical treatments that may help slow its progression, there is currently no cure for Duchenne. C-Path launched the D-RSC in partnership with Parent Project Muscular Dystrophy (PPMD) to establish drug development tools that can accelerate clinical progress of new therapies for the disease.

More information: www.cdisc.org/standards/therap … e-muscular-dystrophy

Provided by Critical Path Institute
Citation: C-Path and CDISC announce therapeutic area user guide for Duchenne Muscular Dystrophy (2017, October 18) retrieved 28 March 2024 from https://medicalxpress.com/news/2017-10-c-path-cdisc-therapeutic-area-user.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

New CDISC data standard aids development of therapies for Ebola virus

1 shares

Feedback to editors